Companies

A global leading pharmaceutical R&D and manufacturing platform spanning Chemistry, Testing and Biology businesses. Its unique CRDMO model connects drug discovery through commercial manufacturing. H1 2026 revenue was RMB 28.9B with a RMB 66.4B backlog.

A global leading large-molecule CRDMO providing end-to-end services from discovery through manufacturing, with a global network connecting China, the US, Ireland, Germany and Singapore. H1 2026 revenue of RMB 11.8B (+18.4%), adjusted net profit of RMB 3.9B (+38.6%), with 1,064 integrated projects; hit its 1,000th integrated project milestone in July 2026.

The global leading bioconjugate CRDMO with a one-stop ADC development and manufacturing platform. H1 2026 revenue of RMB 3.70B (+37.0% AER) with adjusted net profit attributable to owners of RMB 1.03B (+37.4%), 814 global clients and 328 iCMC programs; the Singapore BCM3 line completed GMP release in August 2026.

A controlled subsidiary of WuXi XDC, BioDlink is a global biologics and bioconjugate (ADC/XDC) CDMO providing end-to-end services from early R&D through commercial manufacturing. Built on an integrated one-base platform and proprietary technologies such as GL-DisacLink®, BDKcell® and BDKLyo®, it operates four commercial manufacturing lines with large-scale sterile fill-finish capability, backed by a global GMP-aligned quality system accredited by Japan's PMDA. H1 2026 CDMO revenue reached RMB 199M, up 157% YoY.

An international life-science services company with an end-to-end platform spanning drug discovery, preclinical and clinical development across small molecules, large molecules and cell & gene therapy. Operating in China, the US and the UK with 27,000+ employees.

A global, technology-driven one-stop CDMO serving 1,100+ clients worldwide. Small molecules remain the core while chemical macromolecules (peptides/oligonucleotides, TIDES) enter rapid monetization — peptide capacity will reach 69,000 L by end-2026.

A leading small-molecule API CDMO. Subsidiary Porton Bio focuses on CGT CDMO with an end-to-end platform covering plasmids, viral vectors and cell therapies, and obtained its Drug Manufacturing License (C) in August 2026 to enter commercial-stage manufacturing. That same month, Dr. Yongli Zhong, former Merck Principal Scientist, joined as CSO to strengthen process-technology innovation.

The world's largest-capacity mAb CDMO with 845,000 L total capacity (including the US Rockville site), rising to 1.325M L at Songdo once Bio Campus II is complete. Accelerating multi-modality expansion in peptides (PolyPeptide acquisition) and ADCs.

A Swiss-headquartered global CDMO giant spanning biologics, advanced synthesis (small molecules/bioconjugates), drug product and cell & gene therapy. Built end-to-end ADC capability on the integrated Synaffix platform, with ongoing expansion in Visp, Stein and Vacaville.

A clinical-stage generative-AI-driven drug-discovery company (HKEX: 3696) that applies its AI platform from target discovery through clinical candidates and monetizes via out-licensing and R&D partnerships. H1 2026 revenue reached US$106.3M (+287.2%) with its first profitable half-year; YTD BD contract value reached ~US$7.3B.